Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

clinical trials. Those children not optimized on DAYTRANA from the previous trials entered a four- week stepwise DAYTRANA dose-optimization phase. All children then entered an 11-month DAYTRANA dose maintenance phase. DAYTRANA was applied each morning to the hip area and worn for approximately nine hours daily. During the dose- optimization phase, titration to a higher dose was permitted after a minimum of three days. Tapering to a lower dose was permitted throughout the dose optimization period and dose adjustments were also permitted during the dose maintenance period.

All of the children in this open-label, flexible-dose trial participated in one of four trials in which the children previously received DAYTRANA, OROS methylphenidate or a placebo. All of the children previously used DAYTRANA for at least a minimum of three days and a maximum of 37 months. While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re- evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

Children were diagnosed with ADHD using DSM-IV-TR(R) criteria. Researchers assessed safety and tolerability, through physical exams, skin evaluations, laboratory tests, and monitoring of vital signs, including ECGs throughout the study.

The ADHD-RS-IV assesses 18 individual symptoms of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR(R)), a publication of the American Psychiatric Association.

Of the 327 children enrolled, 157 completed the study. Investigators used data from the intent-to-treat population (324 children) for the efficacy evaluations. Of the safety population (326 children) 7 percent withdrew due to skin irritation at the patch application site, and 9 percent withdrew due to adverse even
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
(Date:2/27/2015)... , Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. ... technologies company, today announced financial results for its first ... the three months ended December 31, 2014, revenue was ... quarter was $229,820 or $0.02 per share.  ... said "I am very pleased with the significant progress ...
(Date:2/27/2015)... February 27, 2015 ... Überwachungssystem für kongestive Herzinsuffizienz (CHF) in seiner ...     Die ... neuartiges Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz ... sie ein Finanzierungsvorhaben über 5 Mio. USD ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... Data Show Prophylaxis Treatment with Kogenate FS Reduces ... Children with No Pre-Existing,Joint Damage, BERKELEY, Calif., ... the U.S. Food and Drug Administration (FDA) has,approved ... reduce the frequency of bleeding episodes and the ...
... Awareness and Bring Hope to Millions,of Children in ... children,across the globe are without parental care due ... disease. SOS Children,s Villages-USA (SOS-USA) is,observing World Orphan ... orphans,worldwide., To view the Multimedia News Release, ...
Cached Medicine Technology:FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... WI (PRWEB) February 28, 2015 ... designation recognizes Mercy Harvard Hospital as stroke capable by ... be brought via ambulance to Mercy Harvard Hospital. , ... state to indicate their ability to treat stroke according ... designation allows ambulances transporting stroke patients to bypass hospitals ...
(Date:2/28/2015)... February 28, 2015 Memphis, TN: MedixSafe ... 2015, for a new security reader named Guardian ... reader is a new biometric scanner that significantly ... new features, the new biometric scanner provides fast ... administrators. , MedixSafe narcotics lockers with ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
(Date:2/27/2015)... Santa Clara, CA (PRWEB) February 27, 2015 ... Integrated Passive Devices (IPD), has introduced miniature, wire bondable, ... Brightness and Power LED markets. The ESD88NP ... high transient currents away from sensitive LED and IC ... compared to Multilayer Varistors (MLV). All devices meet ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... and calcium have been the focus of much research since ... in 1997. Known as Dietary Reference Intakes, the values for ... nutrition and provide the scientific basis for the development of ... DRIs for these two nutrients are presented in a new ...
... found an effective two-part treatment for microtears in the hamstring: ... with "dry-needling," in which repeated needle punctures cause controlled internal ... presented today at the annual meeting of the Radiological Society ... blood where it is needed at the site of a ...
... "We blame kids for being fat, we blame kids for being ... not feeding their kids right," says Terrance Wade, the Canada Research ... of these things are not based on individual choices because your ... Wade is completing a five-year study funded by the Heart ...
... (November 29, 2010) Whitehead Institute researchers have shown ... (miR-125b) can independently cause leukemia and accelerate the disease,s ... edition of the Proceedings of the National Academy of ... but in humans and mice, can upregulation of a ...
... We Die: Reflections on Life,s Final Chapter, Sherwin B. Nuland, ... of end-of-life care today, progress in palliative care, and areas ... published in 1994 and won the National Book Award for ... by describing the physical deterioration that occurs with heart attack, ...
... an innovative use of cell phone records, researchers at UCLA, ... that women appear to avoid contact with their fathers during ... on these high-fertility days and they hang up with them ... a UCLA associate professor of communication in whose lab the ...
Cached Medicine News:Health News:Researchers use patient's own blood to treat hamstring injury 2Health News:Up to 8 percent of Canadian children suffer from elevated blood pressure 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:Contact with dads drops when women ovulate 2Health News:Contact with dads drops when women ovulate 3Health News:Contact with dads drops when women ovulate 4
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Inquire...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: